Related references
Note: Only part of the references are listed.Denosumab
Allan Lipton et al.
Current Opinion in Supportive and Palliative Care (2013)
Increases in bone turnover marker levels at an early phase after starting zoledronic acid predicts skeletal-related events in patients with prostate cancer with bone metastasis
Kouji Izumi et al.
BJU INTERNATIONAL (2012)
Dasatinib combined with docetaxel for castration-resistant prostate cancer
John C. Araujo et al.
CANCER (2012)
Biochemical markers of bone turnover and clinical outcomes in men with prostate cancer
Fred Saad et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2012)
Significance of serum osteoprotegerin and receptor activator of nuclear factor κB ligand in Japanese prostate cancer patients with bone metastasis
Naoto Kamiya et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2011)
Denosumab and Changes in Bone Turnover Markers During Androgen Deprivation Therapy for Prostate Cancer
Matthew R. Smith et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Novel Therapies for Metastatic Castrate-Resistant Prostate Cancer
Farshid Dayyani et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
Karim Fizazi et al.
LANCET (2011)
Once-daily Dasatinib: Expansion of Phase II Study Evaluating Safety and Efficacy of Dasatinib in Patients With Metastatic Castration-resistant Prostate Cancer
Evan Y. Yu et al.
UROLOGY (2011)
Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer
S. Rajpar et al.
ANNALS OF ONCOLOGY (2010)
Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro
Patrick Garnero et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Application of a Fracture Risk Algorithm to Men Treated With Androgen Deprivation Therapy for Prostate Cancer
Philip J. Saylor et al.
JOURNAL OF UROLOGY (2010)
Implications of Serum Bone Turnover Markers in Prostate Cancer Patients With Bone Metastasis
Naoto Kamiya et al.
UROLOGY (2010)
Bone-marker levels in patients with prostate cancer: potential correlations with outcomes
Fred Saad et al.
Current Opinion in Supportive and Palliative Care (2010)
Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer
Evan Y. Yu et al.
CLINICAL CANCER RESEARCH (2009)
Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer
Matthew R. Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid
Allan Lipton et al.
CANCER (2008)
Bone markers and their prognostic value in metastatic bone disease: Clinical evidence and future directions
Robert Coleman et al.
CANCER TREATMENT REVIEWS (2008)
Molecular mechanisms and treatment of bone metastasis
Gregory A. Clines et al.
EXPERT REVIEWS IN MOLECULAR MEDICINE (2008)
Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer
Choichiro Ozu et al.
INTERNATIONAL JOURNAL OF UROLOGY (2008)
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic acid for detection of bone metastases progression
Michael Lein et al.
EUROPEAN UROLOGY (2007)
A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: A TAX327 study analysis
Andrew J. Armstrong et al.
CLINICAL CANCER RESEARCH (2007)
Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: A longitudinal approach
N. Koopmans et al.
JOURNAL OF UROLOGY (2007)
Biochemical markers of bone turnover in patients with localized and metastasized prostate cancer
Axel Hegele et al.
BJU INTERNATIONAL (2007)
Optimal management of metastatic bone disease
Pierre Major
EUROPEAN JOURNAL OF ONCOLOGY NURSING (2007)
Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappa B ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton
Giannis Mountzios et al.
ACTA ONCOLOGICA (2007)
Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation
Gaoping Chen et al.
CANCER (2006)
Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma
K Brasso et al.
PROSTATE (2006)
Serum amino-terminal propeptide of type 1 procollagen (P1NP) in prostate cancer: A potential predictor of bone metastases and prognosticator for disease progression and survival
R Thurairaja et al.
UROLOGIA INTERNATIONALIS (2006)
BSP and RANKL induce osteoclastogenesis and bone resorption synergistically
P Valverde et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid
RE Coleman et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The role of markers of bone remodeling in multiple myeloma
E Terpos et al.
BLOOD REVIEWS (2005)
Urinary osteocalcin as a marker of bone metabolism
KK Ivaska et al.
CLINICAL CHEMISTRY (2005)
Diagnostic value of bone remodeling markers in the diagnosis of bone metastases in patients with breast cancer
D Pectasides et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2005)
Risk of fracture after androgen deprivation for prostate cancer
VB Shahinian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors
JE Brown et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread:: Diagnostic and prognostic implications
K Jung et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays
LJ Lombardo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Effects of conadotropin-releasing hormone agonists on bone metabolism markers and bone mineral density in patients with prostate cancer
Y Miyaji et al.
UROLOGY (2004)
Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors - A randomized, phase III, double-blind, placebo-controlled trial
LS Rosen et al.
CANCER (2004)
Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer
F Saad et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Serum osteoprotegerin and receptor activator of nuclear factor-κ B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer
K Jung et al.
JOURNAL OF UROLOGY (2003)
Markers of bone remodeling in metastatic bone disease
B Fohr et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma - A randomized, double-blind, multicenter, comparative trial
LS Rosen et al.
CANCER (2003)
Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer
S Halabi et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases
JJ Body et al.
CANCER (2003)
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma
F Saad et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2002)
Skeletal fractures negatively correlate with overall survival in men with prostate cancer.
MG Oefelein et al.
JOURNAL OF UROLOGY (2002)
Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs
D Mittan et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2002)
The clinical use of bone resorption markers in patients with malignant bone disease
RE Coleman
CANCER (2002)
Prostate-specific antigen induces osteoplastic changes by an autonomous mechanism
H Yonou et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2001)
Minireview: The OPG/RANKL/RANK system
S Khosla
ENDOCRINOLOGY (2001)
Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer
M Noguchi et al.
JOURNAL OF UROLOGY (2001)
Routine bone scans in patients with prostate cancer related to serum prostate-specific antigen and alkaline phosphatase
LFA Wymenga et al.
BJU INTERNATIONAL (2001)
Metastatic bone disease: clinical features, pathophysiology and treatment strategies
RE Coleman
CANCER TREATMENT REVIEWS (2001)
Osteoprotegerin and rank ligand expression in prostate cancer
JM Brown et al.
UROLOGY (2001)
Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: Loss of antigenicity by treatment with cathepsin K
ML Sassi et al.
BONE (2000)
Markers of bone turnover for the management of patients with bone metastases from prostate cancer
P Garnero et al.
BRITISH JOURNAL OF CANCER (2000)
Progressive osteoporosis during androgen deprivation therapy for prostate cancer
HW Daniell et al.
JOURNAL OF UROLOGY (2000)
Share Paper
